Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi all,
I'm Falon and I'm a ENZCaddict:)
20.5 years Air Force. (1977-1998).
Simply fabulous time with no war but the cold war.
In Basic training we had a trainee that was a black belt in Tae Kwon Do and had his own school in Knoxville, Tn. He basically got a sweet heart of a deal jail (drug related) or the military. Thing is he didn't have to do the normal term of 4 years. He had to go thru basic and spend 2 years at the AF Academy teaching martial arts to cadets thanks to his uncle the then Senator Howard Baker. He was really a nice person and also was of all things, a flower child of Charles Manson. After basic we all got our orders to Technical Training and his orders to the Academy hadn't surface yet and I can still hear him today "I gonna call my uncle".
Why do you think this is a scam?
Having an opinion doesn't it make it so.
There is a lot of that going on in the good ole USA.
Listed below are some facts about ENZC that the company released in the Enzolytics, Inc. 2020 Year End Update.
Now do understand that ENZC could be lying their ASSES OFF and we investors are up the creek or down the sewer. That is the RISK we are willing to take.
What do the facts say about this stock:
1. Currently operating out of a lab at Texas A&M University in the University's Institute for Preclinical Studies.
2. Since the signing of the original non-binding letter of intent, the Company has filed two annual reports and eight quarterly reports, with the required OTC alternative reporting supplemental information, and will soon be filing the last quarterly filing and opinion letter with OTC Markets needed to bring the Company to a current status. The Company is an OTC Market Alternative Standard Reporting entity and is not fully reporting. All of the information that would be required in SEC reporting is included in our Supplemental Information filings and is current.
3. Testing of the newly produced monoclonal antibodies is also being arranged. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France.
4. The Company is in the process of GMP production of the peptide necessary for the validation process, a required step leading to its availability for patient therapy. Regarding the production of the peptide for validation, the Company is reviewing proposals from several CRO labs for such production of this required form of the therapeutic.
5. Enzolytics has also filed a new U.S. Patent covering an immunotherapy treatment applicable for treating Multiple Sclerosis.
6. In addition to these successes, we have been very successful in raising necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.
7. The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years. We believe this step, along with the reorganization under Section 251 G that was initiated prior to the closing of the combination agreement, will significantly enhance the equity position of the Company.
8. Currently, the Company has requested proposals from several PCAOB accounting firms to provide quotes for Audits of the Company's current and prior year Financial Statements in order to become fully reporting. Bids were requested to be provided by mid-January, and the Company anticipates making a decision by the end of January 2021.
9. By combining our expertise with outside professionals and trusted consultants, we have succeeded in less than three months in accomplishing each of these items - as well as others.
I wonder what could ENZC accomplish in the next three months?
Answered questions from the Enzolytics, Inc. 2020 Year End Update
Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
Has ENZC already produced monoclonal antibodies?
If so What is going on with them?
Testing of the newly produced monoclonal antibodies is also being arranged. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France.
The answer to both questions in the very next paragraph.
Yes
Testing being arranged for the newly and now produced monoclonal antibodies.
Dr. Ronald Moss has joined our team as Medical Advisor, adding significant and highly recognized experience. With his assistance, we are advancing our patented antiviral peptide that has been successfully tested in clinical trials at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. The Company is in the process of GMP production of the peptide necessary for the validation process, a required step leading to its availability for patient therapy. Regarding the production of the peptide for validation, the Company is reviewing proposals from several CRO labs for such production of this required form of the therapeutic.
What is GMP production?
What are CRO labs?
Google says the answers are:
Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
To simplify this, GMP helps to ensure the consistent quality and safety of products by focusing attention on five key elements, which are often referred to as the 5 P's of GMP—people, premises, processes, products and procedures (or paperwork).
GMPs are enforced in the United States by the U.S. Food and Drug Administration (FDA), under Title 21 CFR. The regulations use the phrase "current good manufacturing practices" (CGMP) to describe these guidelines.
A contract research organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. ... CROs range from large, international full-service organizations to small, niche specialty groups.
Some questions to ponder that hopefully will be revealed in the upcoming days, weeks and months?
Who pulled ENZC into the Texas A&M Institute for Preclinical Studies?
How close is ENZC getting a product in the marketplace?
What big Pharma will be the first to partner/license with ENZC?
What will be in the first PR after going current?
What will hit the marketplace first, a monoclonal antibody for HIV or SARS-CoV-2?
What action will give the biggest boost to share appreciation?
When will a major news outlet do a story about ENZC?
From today's Supplemental Filing:
C. Describe the issuers’ principal products or services, and their markets:
Enzolytics, Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. The Company is dedicated to the commercialization of these License rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus’ peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Enzolytics, Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
ENZC has never went more than 8 days without releasing a financial report since the last one while trying to get current.
Last time I addressed going no more than 4 days red and we went 5. It all worked out in the end.
Hopefully this time ENZC stay with the trend.
There have been 7 Financial reports released:
3 on a Tuesday
1 on a Wednesday
1 on a Thursday
2 on a Friday
Just saying
ENZC financial reporting for getting current timeline:
November 5, 2020 (The journey begins)
Supplemental Information - For the year ended 12-31-2018
Supplemental Information - For the period ended March 31, 2019
Annual Report - Annual Report for the Year Ended December 31, 2018
November 13, 2020 (8 days after last report)
Quarterly Report - For the period ended March 31, 2019
November 20, 2020 (7 days after last report)
Quarterly Report - For the period ended June 30, 2019
Supplemental Information - For the period ended June 30, 2019
Supplemental Information - For the period ended September 30, 2019
November 24, 2020 (4 days after last report)
Quarterly Report - For the period ended September 30, 2019
December 2, 2020 (8 days after last report)
Supplemental Information - Supplemental Information for the Year Ended December 31, 2019
December 8, 2020 (6 days after last report)
Annual Report - Annual Report for the Year Ended December 31, 2019
December 15, 2020 (7 days after last report)
2020 1st Quarter 10Q
December 23, 2020 (8 days after last report)
2020 2nd Quarter 10Q
Based on previous released reports one can expect FINAL report:
December 28-Jan 1, 2021
2020 3rd Quarter 10Q (TOMORROW)
Reports needed for Current Information: 1
2018 10K Completed
2019 1st Quarter 10Q Completed
2019 2nd Quarter 10Q Completed
2019 3rd Quarter 10Q Completed
2019 10K Completed
2020 1st Quarter 10Q Completed
2020 2nd Quarter 10Q Completed
2020 3rd Quarter 10Q (The journey ends)
CURRENT INFORMATION
PINK
To qualify for Current Information, a non-reporting Pink company may subscribe to the OTC Disclosure & News Service and publish current information pursuant to OTC Markets’ Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:
Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
Like I said:
I don't have you blocked.
I retired from the military (Intell).
You are one of the most predictive assets on these boards.
You say red and GREEN comes out.
I don't have you blocked.
I retired from the military (Intell).
You are one of the most predictive assets on these boards.
Like yesterday on CBB* you said:
There have been 7 Financial reports released:
3 on a Tuesday
1 on a Wednesday
1 on a Thursday
2 on a Friday
Just saying
ENZC financial reporting for getting current timeline:
November 5, 2020 (The journey begins)
Supplemental Information - For the year ended 12-31-2018
Supplemental Information - For the period ended March 31, 2019
Annual Report - Annual Report for the Year Ended December 31, 2018
November 13, 2020 (8 days after last report)
Quarterly Report - For the period ended March 31, 2019
November 20, 2020 (7 days after last report)
Quarterly Report - For the period ended June 30, 2019
Supplemental Information - For the period ended June 30, 2019
Supplemental Information - For the period ended September 30, 2019
November 24, 2020 (4 days after last report)
Quarterly Report - For the period ended September 30, 2019
December 2, 2020 (8 days after last report)
Supplemental Information - Supplemental Information for the Year Ended December 31, 2019
December 8, 2020 (6 days after last report)
Annual Report - Annual Report for the Year Ended December 31, 2019
December 15, 2020 (7 days after last report)
2020 1st Quarter 10Q
December 23, 2020 (8 days after last report)
2020 2nd Quarter 10Q
Based on previous released reports one can expect FINAL report:
December 28-Jan 1, 2021
2020 3rd Quarter 10Q
Reports needed for Current Information: 1
2018 10K Completed
2019 1st Quarter 10Q Completed
2019 2nd Quarter 10Q Completed
2019 3rd Quarter 10Q Completed
2019 10K Completed
2020 1st Quarter 10Q Completed
2020 2nd Quarter 10Q Completed
2020 3rd Quarter 10Q (The journey ends)
CURRENT INFORMATION
PINK
To qualify for Current Information, a non-reporting Pink company may subscribe to the OTC Disclosure & News Service and publish current information pursuant to OTC Markets’ Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:
Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
ENZC
Potential Catalysts to move the stock price up:
2nd Quarterly Report DONE
Yield Sign up Done
3rd Quarterly Report imminent!!!
Attorney letter
Current Information Status
PR about updates from Texas A&M
PR about funding
PR about ENZC updated Business Activities
PR about IND submittal
PR about FDA approval
PR about Clinical trials/studies
PR about Licensing deals
PR about partnerships
PR about Production
The above list is not inclusive of all the possible information that will flow from ENZC.
It is just a glimpse of activities in the works. Also while all the Catalysts will not move the stock price up they will move ENZC forward.
The 2nd quarter Supplemental Information was released December 17, 2020 with the 2nd Quarterly Report in the works.
The Quarterly Report - For the period ended June 30, 2020 was released December 23, 2020.
YIELD Sign up Current Information imminent!!!
3rd Quarter Report and Attorney letter need to go to CURRENT Information.
From ENZC website:
Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. Immunotech BG-Europe , under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS.
ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe.
Additionally, ImmunoTech BG-Europe has informed Enzolytics that they will be seeking to register the ImmunH product as a ImmuneModulator, allowing use as an adjunct in additional applications to regulate or normalize the Immune System.
https://enzolytics.com/immunh-bg%2Feurope
PLANO, TX / ACCESSWIRE / September 16, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas.
With its technology for producing fully human monoclonal antibodies against numerous infectious diseases viruses, including those targeting the HIV-1 virus [http://www.bioclonetics.com/effectiveness.html ] and recognizing asignificant correlative structure between the HIV virus and the SARS-CoV-2 (COVID-19) virus, BioClonetics has been invited by the National Science Foundation (NSF) to submit an application for funding for development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary technology. Such application to the NSF and a corresponding application to the NIH are now pending.
https://www.bloomberg.com/press-releases/2020-09-16/enzolytics-inc-announces-execution-of-letter-of-intent-with-bioclonetics-immunotherapeutics-inc-with-additional-u
NSF Proposal and Award Process
PHASE I – PROPOSAL PREPARATION AND SUBMISSION – 90 DAYS
PHASE II – PROPOSAL REVIEW AND PROCESSING – 6 MONTHS
PHASE III – AWARD PROCESSING – 30 DAYS
https://www.nsf.gov/attachments/116169/public/nsf_proposal_and_award_process.pdf
NIH Application Process:
Understand Due Dates, Preparation Time & Review Cycles
As you consider which opportunity best fits your research plans, know that the opportunity you choose will affect the timing of your application. For investigator-initiated applications, due dates vary by activity code (e.g., R01 or R21) and grant type (e.g., new or resubmission).
Get Your Application in Early
The NIH Guide announcement for your funding opportunity announcement (FOA) will give you the NIH due date, a deadline for submitting your application electronically.
But note that your institution’s internal deadline is your true key due date, not the NIH date. Even so, the NIH due date will trigger other dates relevant to your submission.
For an investigator-initiated application (including some program announcements), you will apply by one of NIH's three standard due dates (except for institutional training grants), called review and award cycles I, II, and III.
For example, new non-AIDS R01 applications are due February 5, June 5, and October 5.
Due dates for other applications are affected by various factors:
AIDS and AIDS-related research
Activity code, e.g., P series (program projects), U01 (cooperative agreements), or R41 to R44 (small business applications)
Grant type, e.g., new, renewal, or resubmission
Find all due dates for investigator-initiated grant applications on NIH Standard Due Dates for Competing Applications.
Check the FOA for instructions specific to the NIH institute or center. For example, at NIAID, T32 and T35 training grants have two annual deadlines: January 25 and September 25 for non-AIDS, and January 7 and May 7 for AIDS-related applications.
Here are a few more items you need to know about NIH receipt dates:
Deadlines can be affected by weekends, holidays, and certain emergency or natural disaster situations. Read more about these timing exceptions at Submission Policies.
Each request for applications (RFA) has its own (usually one-time) due date stated in the FOA.
Some program announcements (PA) also have their own special due dates; read the FOA to be sure.
If you are appointed to a standing NIH review or advisory committee, the NIH Continuous Submission policy allows you flexibility for certain standard due dates. Check the policy site and Frequently Asked Questions for details on who qualifies and which opportunities allow continuous submission.
Review and award. After the due date, it typically takes between 8 and 20 months to go through both levels of review and get an award—three months less for AIDS and AIDS-related research—assuming you succeed on the first try. For details, see Timeline for Assignment, Review, and Council and Timeline for Funding Decisions.
Understanding Review Cycles
Though we describe the differences in the cycles below for your information, we advise against factoring the review cycle into your decision about which due date to target for an NIAID application.
At NIAID, there is no significant correlation between review cycle and your time to award. We issue awards at about the same pace, regardless of application cycle.
Among NIH's institutes and centers, NIAID has one of the fastest average times to award. As of February 2017, our median time from summary statement to award was about 100 days for all three review cycles.
https://www.niaid.nih.gov/grants-contracts/due-dates-preparation-time-review
It would be impossible to give any timeline on therapeutic treatment/vaccine with the available information.
That being said it is encouraging that ENZC is working at Texas A&M Institute for Preclinical Studies giving them a wealth of services and expertise to help bring them closer to the endeavors they are trying to achieve,
The Texas A&M Institute for Preclinical Studies (TIPS) provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry, and engineering.
https://tips.tamu.edu/
Sadly she passed away last year. (updated)
https://en.wikipedia.org/wiki/Patricia_Nell_Warren
Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?
CEOCFO: What are you looking at regarding COVID?
Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.
For example, we all now know that President Trump received a combination of two Regeneron antibodies. Eli Lilly has also produced an anti-CoronaVirus antibody. However, what we do not know is whether those antibodies will be successful as the virus mutates. As I mentioned, there are now known 16,000 different variants to the CoronaVirus and immutable sites must be the targeted in order to be effective in the long run.
Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. The process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.
Why is ENZC different from other antibodies?
CEOCFO: From your recent press release, you have a proprietary methodology for producing fully human OGG1 monoclonal antibodies. How is your approach different?
There are an infinite number of distinct anti-HIV and anti-CoronaVirus monoclonal antibodies that can exist – some disease neutralizing, some perhaps of no benefit and some perhaps disease enhancing. Thus, specific antibodies that neutralize are necessary to provide an effective therapy. Enzolytics’ method of producing effective monoclonal antibodies focuses on identifying immutable binding sites on the virus and then creating monoclonal antibodies that bind to such sites and neutralize the virus. In this way, the virus cannot mutate around the therapy. For example, the antibodies administered to President Trump to treat him for the CoronaVirus, may target a site on the virus that will mutate. Thus, the same antibodies may not be effective for you or me later if the CoronaVirus has mutated, changed structure, at this binding site. Our anti-HIV monoclonal antibody binds to a site on the HIV virus that is conserved in 98% of the more than 6000 strains of the HIV-1 viruses now known, sequenced and archived in the Los Alamos National Laboratory HIV Database. The same will have to be achieved for successful anti-CoronaVirus monoclonal antibodies.
CEOCFO: From your recent press release, you have a proprietary methodology for producing fully human OGG1 monoclonal antibodies. How is your approach different?
In contrast, our method starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the target virus. The primary distinction of our process for creating fully human monoclonals is the starting point – namely from human “immune-B cells” obtained from humans who have survived successfully from a "natural" infection. From these human “immune-B cells”, we then produce antibodies that target conserved immutable sites (neutralizable epitopes) on the virus’ surface envelope proteins – which will thereby avoid “virus escape”, which has been frequently demonstrated to occur as a consequence of mutations in the HIV virus surface structure.
Additionally, our antibodies retain the original natural antibody affinity and specificity, and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, in what is called the camelid structure form, and, in the recombinant form will have greater accessibility to the virus binding sites not accessible with a whole antibody. We believe that our method is one that produces an antibody which will be more effective with less risk of adverse reaction.
Source: https://www.ceocfointerviews.com/enzolytics20.html
All stocks need liquidity so all traders day, short and long day are welcome.
Results from the company will ultimately determine price movement.
MMs don't matter as the keep the stock moving based on supply and demand.
ENZC has some upcoming results that should be very favorable in the stock price movement.
Market Sentiment
Market sentiment refers to the psychology of market participants, individually and collectively. This is perhaps the most vexing category. Market sentiment is often subjective, biased, and obstinate. For example, you can make a solid judgment about a stock's future growth prospects, and the future may even confirm your projections, but in the meantime, the market may myopically dwell on a single piece of news that keeps the stock artificially high or low. And you can sometimes wait a long time in the hope that other investors will notice the fundamentals.
Market sentiment is being explored by the relatively new field of behavioral finance. It starts with the assumption that markets are apparently not efficient much of the time, and this inefficiency can be explained by psychology and other social science disciplines. The idea of applying social science to finance was fully legitimized when Daniel Kahneman, PhD, a psychologist, won the 2002 Nobel Memorial Prize in Economic Sciences (the first psychologist to do so). ? Many of the ideas in behavioral finance confirm observable suspicions: that investors tend to overemphasize data that come easily to mind; that many investors react with greater pain to losses than with pleasure to equivalent gains; and that investors tend to persist in a mistake.
Liquidity
Liquidity is an important and sometimes under-appreciated factor. It refers to how much interest from investors a specific stock attracts. Wal-Mart's stock, for example, is highly liquid and therefore highly responsive to material news; the average small-cap company is less so.3? Trading volume is not only a proxy for liquidity, but it is also a function of corporate communications (that is, the degree to which the company is getting attention from the investor community). Large-cap stocks have high liquidity—they are well followed and heavily transacted. Many small-cap stocks suffer from an almost permanent "liquidity discount" because they simply are not on investors' radar screens.
NEWS
While it is hard to quantify the impact of news or unexpected developments inside a company, industry or the global economy, you can't argue that it does influence investor sentiment. The political situation, negotiations between countries or companies, product breakthroughs, mergers and acquisitions and other unforeseen events can impact stocks and the stock market. Since securities trading happens across the world and markets and economies are interconnected, news in one country can impact investors in another, almost instantly.
The Bottom Line
Different types of investors depend on different factors. Short-term investors and traders tend to incorporate and may even prioritize technical factors. Long-term investors prioritize fundamentals and recognize that technical factors play an important role. Investors who believe strongly in fundamentals can reconcile themselves to technical forces with the following popular argument: technical factors and market sentiment often overwhelm the short run, but fundamentals will set the stock price in the long-run. In the meantime, we can expect more exciting developments in the area of behavioral finance, especially since traditional financial theories cannot seem to explain everything that happens in the market.
ENZC
Potential Catalysts to move the stock price up:
2nd Quarterly Report DONE
Stop Sign down/Yield Sign up Next UP
3rd Quarterly Report
Attorney letter
Current Information Status
PR about updates from Texas A&M
PR about funding
PR about ENZC updated Business Activities
PR about IND submittal
PR about FDA approval
PR about Clinical trials/studies
PR about Licensing deals
PR about partnerships
PR about Production
The above list is not inclusive of all the possible information that will flow from ENZC.
It is just a glimpse of activities in the works. Also while all the Catalysts will not move the stock price up they will move ENZC forward.
Tomorrow ENZC is at a crossroads as the stock price has never closed in the red more than 4 days in a row.
Will the trend change?
Yes it did.
ENZC closing price went for 5 days red and then a reversal to green and BOOM!!!!!!
The 2nd quarter Supplemental Information was released December 17, 2020 with the 2nd Quarterly Report in the works.
The Quarterly Report - For the period ended June 30, 2020 was released December 23, 2020.
Stop Sign down YIELD Sign up imminent!!!
3rd Quarter Report and Attorney letter need to go to CURRENT Information.
MERRY CHRISTMAS and a HAPPY NEW YEAR to ALL!!!!
YES I”M SHOUTING
Really,
That is all you got! ha
Let me help you.
What to expect from ENZC:
1. Great Management
2. 2nd Quarterly Report
3. Stop Sign down/Yield Sign up
4. 3rd Quarterly Report
5. Attorney letter
6. Current Information Status
7. PR about updates from Texas A&M
8. PR about funding
9. PR about ENZC updated Business Activities
10. PR about IND submittal
11. PR about FDA approval
12. PR about Clinical trials/studies
13. PR about Licensing deals
14. PR about partnerships
15. PR about Production
What to expect from Bashing:
Nothing worth repeating.
You are in an OTC stock which is one of the worst places to invest your money.
It is up to you to decide when to hold and when to sell.
You have to do your own Due Diligence.
No one and I mean no one here is your friend.
You have to take what is posted on these boards with a grain of salt.
There are plenty of wolves in sheep clothing on these boards.
You have posters saying this may go to the moon and you have posters saying we are going back to trips.
What you have to determine has nothing to do with what the posters are saying but with what the company is doing.
Questions for you.
Why is ENZC at Texas A&M?
Is ENZC filing the past financial report to get current?
Who is on ENZC Board of Directors?
Results move stock prices!
There has been 6 Financial reports released:
3 on a Tuesday
1 on a Thursday
and
2 on a Friday
Just saying
ENZC financial reporting for getting current timeline:
November 5, 2020 (The journey begins)
Supplemental Information - For the year ended 12-31-2018
Supplemental Information - For the period ended March 31, 2019
Annual Report - Annual Report for the Year Ended December 31, 2018
November 13, 2020 (8 days after last report)
Quarterly Report - For the period ended March 31, 2019
November 20, 2020 (7 days after last report)
Quarterly Report - For the period ended June 30, 2019
Supplemental Information - For the period ended June 30, 2019
Supplemental Information - For the period ended September 30, 2019
November 24, 2020 (4 days after last report)
Quarterly Report - For the period ended September 30, 2019
December 2, 2020 (8 days after last report)
Supplemental Information - Supplemental Information for the Year Ended December 31, 2019
December 8, 2020 (6 days after last report)
Annual Report - Annual Report for the Year Ended December 31, 2019
December 15, 2020 (7 days after last report)
Based on the previous released reports one can expect more reports to be released (updated):
December 21-25, 2020
2020 2nd Quarter 10Q
December 28-Jan 1, 2021
2020 3rd Quarter 10Q
Reports needed for Current Information: 3
2018 10K Completed
2019 1st Quarter 10Q Completed
2019 2nd Quarter 10Q Completed
2019 3rd Quarter 10Q Completed
2019 10K Completed
2020 1st Quarter 10Q Completed
2020 2nd Quarter 10Q (Limited Information Stop Sign down Yield Sign up)
2020 3rd Quarter 10Q (The journey ends)
CURRENT INFORMATION
PINK
To qualify for Current Information, a non-reporting Pink company may subscribe to the OTC Disclosure & News Service and publish current information pursuant to OTC Markets’ Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:
Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
Wow we have our own on-board know-it-all saying it only take a couple of days to get current.
Do we have a reversal in the making?
ENZC
Potential Catalysts to move the stock price up:
1. 2nd Quarterly Report
2. Stop Sign down/Yield Sign up
3, 3rd Quarterly Report
4. Attorney letter
5. Current Information Status
6. PR about updates from Texas A&M
7. PR about funding
8. PR about ENZC updated Business Activities
9. PR about IND submittal
10. PR about FDA approval
11. PR about Clinical trials/studies
12. PR about Licensing deals
13. PR about partnerships
14. PR about Production
The above list is not inclusive of all the possible information that will flow from ENZC. It is just a glimpse of activities in the works. Also while all the catalysts will not move the stock price up they will move ENZC forward.
Tomorrow ENZC is at a crossroads as the stock price has never closed in the red more than 4 days in a row.
Will the trend change?
Hopefully not. Looking for a GREEN close.
The 2nd quarter Supplemental Information was released December 17, 2020 with the 2nd Quarterly Report in the works.
Maybe
Maybe not
Our treatment is different.
Follow the Science:
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with
specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
We are actively moving forward in our production and testing of such antibodies.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113
There have been approximately 45 trading days since October 15, 2020.
ENZC close red 22 times during that period and ENZC closed GREEN the remaining 23 days.
There have been ups and downs however after every down day(s) the stock has ALWAYS recovered.
There are day traders, flippers, short term and long term holders so there will be a lot of volatility until more information is released by the company moving forward such as financial and technology progression updates.
It is starting to look a lot like CHRISTMAS with all the red and GREEN.
ENZC's longest red day trend is 4.
ENZC longest green day trend is 8.
ENZC is a work in progress with untethered potential.
Interesting, Timely, Accurate
FACT no fiction
Date Close Change Change (%) Open High Low Volume
Dec 17 2020 0.0668 -0.0051 -7.09% 0.07 0.0739 0.055 45,708,481
Dec 16 2020 0.0719 -0.0061 -7.82% 0.085 0.085 0.0671 38,276,529
Dec 15 2020 0.078 -0.0149 -16.04% 0.099 0.099 0.07 38,104,671
Dec 14 2020 0.0929 0.0017 1.86% 0.0943 0.10 0.0917 30,121,269
Dec 11 2020 0.0912 0.0011 1.22% 0.09 0.0995 0.0825 25,366,063
Dec 10 2020 0.0901 -0.0089 -8.99% 0.1099 0.1099 0.0625 68,820,498
Dec 09 2020 0.099 0.00 +0.00% 0.099 0.124 0.095 0
Dec 09 2020 0.099 -0.007 -6.6% 0.099 0.124 0.095 52,511,429
Dec 08 2020 0.106 0.0103 10.76% 0.10 0.1195 0.0895 71,798,130
Dec 07 2020 0.0957 0.0207 27.6% 0.0951 0.0978 0.0756 76,474,224
Dec 04 2020 0.075 0.00 +0.00% 0.077 0.083 0.07 0
Dec 04 2020 0.075 0.00 0.0% 0.077 0.083 0.07 51,406,162
Dec 03 2020 0.075 0.00 +0.00% 0.07 0.0879 0.069 0
Dec 03 2020 0.075 0.014 22.95% 0.07 0.0879 0.069 63,106,583
Dec 02 2020 0.061 -0.014 -18.67% 0.0701 0.0724 0.051 117,102,704
Dec 01 2020 0.075 -0.0339 -31.13% 0.1176 0.1176 0.06 289,127,881
Nov 30 2020 0.1089 0.00 +0.00% 0.0795 0.1098 0.055 0
Nov 30 2020 0.1089 0.0587 116.93% 0.0795 0.1098 0.055 180,582,764
Nov 27 2020 0.0502 0.00 +0.00% 0.0381 0.0503 0.0336 0
Nov 27 2020 0.0502 0.0172 52.12% 0.0381 0.0503 0.0336 83,732,472
Nov 26 2020 0.033 0.00 +0.00% 0.042 0.043 0.0275 0
Nov 25 2020 0.033 -0.0063 -16.03% 0.042 0.043 0.0275 247,057,917
Nov 24 2020 0.0393 0.0117 42.39% 0.042 0.0435 0.0301 187,475,502
Nov 23 2020 0.0276 0.00821 42.34% 0.0201 0.031 0.02 258,472,181
Nov 20 2020 0.01939 0.00 +0.00% 0.0135 0.02 0.01305 0
Nov 20 2020 0.01939 0.00634 48.58% 0.0135 0.02 0.01305 207,027,154
Nov 19 2020 0.01305 0.00 +0.00% 0.0129 0.0135 0.0121 0
Nov 19 2020 0.01305 0.00085 6.97% 0.0129 0.0135 0.0121 52,898,508
Nov 18 2020 0.0122 0.0008 7.02% 0.0139 0.0154 0.012 145,940,370
Nov 17 2020 0.0114 0.00184 19.18% 0.0112 0.0115 0.0097 65,500,690
Nov 16 2020 0.009565 0.00047 5.11% 0.0099 0.01 0.0091 52,132,749
Nov 13 2020 0.0091 0.00 +0.00% 0.0084 0.0093 0.0082 0
Nov 13 2020 0.0091 0.0011 13.75% 0.0084 0.0093 0.0082 69,918,285
Nov 12 2020 0.008 -0.0008 -9.09% 0.00885 0.0092 0.0074 44,161,296
Nov 11 2020 0.0088 -0.0006 -6.38% 0.0096 0.0097 0.0085 25,090,942
Nov 10 2020 0.0094 0.0004 4.44% 0.01 0.01 0.009 31,376,569
Nov 09 2020 0.009 0.00 +0.00% 0.0104 0.0104 0.0085 0
Nov 09 2020 0.009 -0.0004 -4.26% 0.0104 0.0104 0.0085 40,820,082
Nov 06 2020 0.0094 -0.0001 -1.05% 0.0098 0.0104 0.0092 41,948,913
Nov 05 2020 0.0095 -0.0012 -11.21% 0.0095 0.0107 0.0091 70,935,119
Nov 04 2020 0.0107 -0.0002 -1.83% 0.0105 0.0114 0.0103 34,712,852
Nov 03 2020 0.0109 0.00 +0.00% 0.0113 0.0118 0.0103 0
Nov 03 2020 0.0109 0.0001 0.93% 0.0113 0.0118 0.0103 44,134,884
Nov 02 2020 0.0108 -0.0019 -14.96% 0.0132 0.0133 0.0107 83,936,600
Oct 30 2020 0.0127 0.00 +0.00% 0.0105 0.014 0.01039 0
Oct 30 2020 0.0127 0.0022 20.95% 0.0105 0.014 0.01039 265,230,348
Oct 29 2020 0.0105 -0.0001 -0.94% 0.0109 0.011 0.01 35,423,211
Oct 28 2020 0.0106 0.00 +0.00% 0.0109 0.0118 0.0095 0
Oct 28 2020 0.0106 0.00035 3.41% 0.0109 0.0118 0.0095 90,735,433
Oct 27 2020 0.01025 0.00005 0.49% 0.0109 0.0109 0.0097 38,529,740
Oct 26 2020 0.0102 0.00 +0.00% 0.012 0.012 0.01 0
Oct 26 2020 0.0102 -0.00155 -13.19% 0.012 0.012 0.01 56,992,881
Oct 23 2020 0.01175 0.00025 2.17% 0.0123 0.0124 0.0103 54,446,244
Oct 22 2020 0.0115 0.00 +0.00% 0.012 0.0128 0.0108 0
Oct 22 2020 0.0115 -0.0003 -2.54% 0.012 0.0128 0.0108 63,559,198
Oct 21 2020 0.0118 0.0015 14.56% 0.0105 0.013 0.0096 134,540,185
Oct 20 2020 0.0103 0.00 +0.00% 0.0105 0.0109 0.0097 0
Oct 20 2020 0.0103 -0.0001 -0.96% 0.0105 0.0109 0.0097 50,701,373
Oct 19 2020 0.0104 -0.0004 -3.7% 0.0119 0.012 0.0095 86,865,904
Oct 16 2020 0.0108 0.00 +0.00% 0.0123 0.0124 0.0099 0
Oct 16 2020 0.0108 -0.0015 -12.2% 0.0123 0.0124 0.0099 100,004,022
Oct 15 2020 0.0123 0.00 +0.00% 0.0139 0.0145 0.0108 0
Oct 15 2020 0.0123 -0.0007 -5.38% 0.0139 0.0145 0.0108 113,626,782
So what are you saying ENZC is going up because ENZC was down 31.13 percent on December 1, 2020 and 18.67 percent on December 2, 2020 however on December 3, 2020 ENZC was up 22.95 percent and on December 7 and 8, 2020 up 27. 6 percent and 10.76 percent respectively.
Red days down totaled 48.8 percent
Green days recovery days totaled 61.31 percent.
Analysis says this is a GREAT buying opportunity for the next leg up.
Dec 02 2020 0.061 -0.014 -18.67% 0.0701 0.0724 0.051 117,102,704
Dec 01 2020 0.075 -0.0339 -31.13% 0.1176 0.1176 0.06 289,127,881
Dec 03 2020 0.075 0.014 22.95% 0.07 0.0879 0.069 63,106,583
Dec 08 2020 0.106 0.0103 10.76% 0.10 0.1195 0.0895 71,798,130
Dec 07 2020 0.0957 0.0207 27.6% 0.0951 0.0978 0.0756 76,474,224
There have been approximately 43 trading days since October 15, 2020.
ENZC close red 20 times during that period and ENZC closed GREEN the remaining 23 days.
There have been ups and downs however after every down day(s) the stock has ALWAYS recovered.
There are day traders, flippers, short term and long term holders so there will be a lot of volatility until more information is released by the company moving forward such as financial and technology progression updates.
There was a low of 0.061 on December 2, 2020 after a high of 0.1098 on November 30, 2020.
There was a high of 0.1195 on December 8, 2020.
ENZC is a work in progress with untethered potential.
Interesting, Timely, Accurate
FACT no fiction
Date Close Change Change (%) Open High Low Volume
Dec 15 2020 0.078 -0.0149 -16.04% 0.099 0.099 0.07 38,104,671
Dec 14 2020 0.0929 0.0017 1.86% 0.0943 0.10 0.0917 30,121,269
Dec 11 2020 0.0912 0.0011 1.22% 0.09 0.0995 0.0825 25,366,063
Dec 10 2020 0.0901 -0.0089 -8.99% 0.1099 0.1099 0.0625 68,820,498
Dec 09 2020 0.099 0.00 +0.00% 0.099 0.124 0.095 0
Dec 09 2020 0.099 -0.007 -6.6% 0.099 0.124 0.095 52,511,429
Dec 08 2020 0.106 0.0103 10.76% 0.10 0.1195 0.0895 71,798,130
Dec 07 2020 0.0957 0.0207 27.6% 0.0951 0.0978 0.0756 76,474,224
Dec 04 2020 0.075 0.00 +0.00% 0.077 0.083 0.07 0
Dec 04 2020 0.075 0.00 0.0% 0.077 0.083 0.07 51,406,162
Dec 03 2020 0.075 0.00 +0.00% 0.07 0.0879 0.069 0
Dec 03 2020 0.075 0.014 22.95% 0.07 0.0879 0.069 63,106,583
Dec 02 2020 0.061 -0.014 -18.67% 0.0701 0.0724 0.051 117,102,704
Dec 01 2020 0.075 -0.0339 -31.13% 0.1176 0.1176 0.06 289,127,881
Nov 30 2020 0.1089 0.00 +0.00% 0.0795 0.1098 0.055 0
Nov 30 2020 0.1089 0.0587 116.93% 0.0795 0.1098 0.055 180,582,764
Nov 27 2020 0.0502 0.00 +0.00% 0.0381 0.0503 0.0336 0
Nov 27 2020 0.0502 0.0172 52.12% 0.0381 0.0503 0.0336 83,732,472
Nov 26 2020 0.033 0.00 +0.00% 0.042 0.043 0.0275 0
Nov 25 2020 0.033 -0.0063 -16.03% 0.042 0.043 0.0275 247,057,917
Nov 24 2020 0.0393 0.0117 42.39% 0.042 0.0435 0.0301 187,475,502
Nov 23 2020 0.0276 0.00821 42.34% 0.0201 0.031 0.02 258,472,181
Nov 20 2020 0.01939 0.00 +0.00% 0.0135 0.02 0.01305 0
Nov 20 2020 0.01939 0.00634 48.58% 0.0135 0.02 0.01305 207,027,154
Nov 19 2020 0.01305 0.00 +0.00% 0.0129 0.0135 0.0121 0
Nov 19 2020 0.01305 0.00085 6.97% 0.0129 0.0135 0.0121 52,898,508
Nov 18 2020 0.0122 0.0008 7.02% 0.0139 0.0154 0.012 145,940,370
Nov 17 2020 0.0114 0.00184 19.18% 0.0112 0.0115 0.0097 65,500,690
Nov 16 2020 0.009565 0.00047 5.11% 0.0099 0.01 0.0091 52,132,749
Nov 13 2020 0.0091 0.00 +0.00% 0.0084 0.0093 0.0082 0
Nov 13 2020 0.0091 0.0011 13.75% 0.0084 0.0093 0.0082 69,918,285
Nov 12 2020 0.008 -0.0008 -9.09% 0.00885 0.0092 0.0074 44,161,296
Nov 11 2020 0.0088 -0.0006 -6.38% 0.0096 0.0097 0.0085 25,090,942
Nov 10 2020 0.0094 0.0004 4.44% 0.01 0.01 0.009 31,376,569
Nov 09 2020 0.009 0.00 +0.00% 0.0104 0.0104 0.0085 0
Nov 09 2020 0.009 -0.0004 -4.26% 0.0104 0.0104 0.0085 40,820,082
Nov 06 2020 0.0094 -0.0001 -1.05% 0.0098 0.0104 0.0092 41,948,913
Nov 05 2020 0.0095 -0.0012 -11.21% 0.0095 0.0107 0.0091 70,935,119
Nov 04 2020 0.0107 -0.0002 -1.83% 0.0105 0.0114 0.0103 34,712,852
Nov 03 2020 0.0109 0.00 +0.00% 0.0113 0.0118 0.0103 0
Nov 03 2020 0.0109 0.0001 0.93% 0.0113 0.0118 0.0103 44,134,884
Nov 02 2020 0.0108 -0.0019 -14.96% 0.0132 0.0133 0.0107 83,936,600
Oct 30 2020 0.0127 0.00 +0.00% 0.0105 0.014 0.01039 0
Oct 30 2020 0.0127 0.0022 20.95% 0.0105 0.014 0.01039 265,230,348
Oct 29 2020 0.0105 -0.0001 -0.94% 0.0109 0.011 0.01 35,423,211
Oct 28 2020 0.0106 0.00 +0.00% 0.0109 0.0118 0.0095 0
Oct 28 2020 0.0106 0.00035 3.41% 0.0109 0.0118 0.0095 90,735,433
Oct 27 2020 0.01025 0.00005 0.49% 0.0109 0.0109 0.0097 38,529,740
Oct 26 2020 0.0102 0.00 +0.00% 0.012 0.012 0.01 0
Oct 26 2020 0.0102 -0.00155 -13.19% 0.012 0.012 0.01 56,992,881
Oct 23 2020 0.01175 0.00025 2.17% 0.0123 0.0124 0.0103 54,446,244
Oct 22 2020 0.0115 0.00 +0.00% 0.012 0.0128 0.0108 0
Oct 22 2020 0.0115 -0.0003 -2.54% 0.012 0.0128 0.0108 63,559,198
Oct 21 2020 0.0118 0.0015 14.56% 0.0105 0.013 0.0096 134,540,185
Oct 20 2020 0.0103 0.00 +0.00% 0.0105 0.0109 0.0097 0
Oct 20 2020 0.0103 -0.0001 -0.96% 0.0105 0.0109 0.0097 50,701,373
Oct 19 2020 0.0104 -0.0004 -3.7% 0.0119 0.012 0.0095 86,865,904
Oct 16 2020 0.0108 0.00 +0.00% 0.0123 0.0124 0.0099 0
Oct 16 2020 0.0108 -0.0015 -12.2% 0.0123 0.0124 0.0099 100,004,022
Oct 15 2020 0.0123 0.00 +0.00% 0.0139 0.0145 0.0108 0
Oct 15 2020 0.0123 -0.0007 -5.38% 0.0139 0.0145 0.0108 113,626,782
Immunotech Laboratories, Inc. Announces Successful Completion of Phase I and Phase II Field Trials of the Company’s Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
August 28, 2014 09:00 AM Eastern Daylight Time
MONROVIA, Calif.--(BUSINESS WIRE)--Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) have been successfully completed.
The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization (“CRO”) to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility.
The toxicity testing of ITV-1 on animals has also been successfully completed as well as a complete pharmacokinetics (PK) analysis of how the treatment is distributed through the blood system. The Company is making its application for the permit to move to Phase III full scale clinical testing on patients. The initial testing will begin upon receipt of the Phase III permit which the Company expects to receive within 60 days of acceptance of the application.
About Immunotech Laboratories, Inc.
Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immuno related disorders.
MONROVIA, CA / ACCESSWIRE / January 25, 2017 / Immunotech Laboratories, Inc. (OTC PINK: IMMB – Greymarket) (the"Company" or "IMMB") announced today the completion of successful clinical Phase III testing on patients suffering from HIV/AIDS of its patented medical product, ITV-1-ImmunH treatment. The clinical trials were conducted through IMMB's subsidiary, Immunotech Laboratories BG – Europe ("IMMB-BG") at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases – "Prof. Ivan Kirov", Sofia Bulgaria. The trials, using the most current state of the art clinical testing methods available, which were approved at the World Practice Show, revealed significant positive results in treating the deadly disease. Data from the final report shows improvement in immune indices in the absolute number of LY, CD3 T, CD4 T, CD8 T, B Ly, NK levels and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and in the CD4/CD8 index. Most importantly, viral loads in approximately 80% of the blood samples of the patients, after completion of the treatment cycles, came back at non-detectable levels. Other important results noted in the summary report were the positive treatment effect on opportunistic infections, compatibility with all other antiviral drugs, high level of tolerance in all patients and the complete lack of any negative side effects.
The full report is available on the Company Website, www.immunotechlab.com. Additional information is available on the website of our subsidiary Immunotech Laboratories BG-Europe – www.immunh.com.
Enzolytics Update
April 16, 2020
PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.
The immediate goals include:
- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF
As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe.
The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.
About ENZOLYTICS;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of HIV/AIDS. Enzolytics is committed to the betterment of health for all mankind and exploring/developing additional applications of its novel immunotherapy compounds to that end.
Enzolytics flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
brezlin,
That was not a beautiful moment it was freaking "PRICELESS":)
There has been 5 Financial reports released:
2 on a Tuesday
1 on a Thursday
and
2 on a Friday
Just saying
ENZC financial reporting for getting current timeline:
November 5, 2020 (The journey begins)
Supplemental Information - For the year ended 12-31-2018
Supplemental Information - For the period ended March 31, 2019
Annual Report - Annual Report for the Year Ended December 31, 2018
November 13, 2020 (8 days after last report)
Quarterly Report - For the period ended March 31, 2019
November 20, 2020 (7 days after last report)
Quarterly Report - For the period ended June 30, 2019
Supplemental Information - For the period ended June 30, 2019
Supplemental Information - For the period ended September 30, 2019
November 24, 2020 (4 days after last report)
Quarterly Report - For the period ended September 30, 2019
December 2, 2020 (8 days after last report)
Supplemental Information - Supplemental Information for the Year Ended December 31, 2019
December 8, 2020 (6 days after last report)
Annual Report - Annual Report for the Year Ended December 31, 2019
Based on the previous released reports one can expect more reports to be released:
December 7-11, 2020
2019 10K Released December 8, 2020
2020 1st Quarter 10Q
December 14-18, 2020
2020 2nd Quarter 10Q
2020 3rd Quarter 10Q
Reports needed for Current Information: 3
2018 10K Completed
2019 1st Quarter 10Q Completed
2019 2nd Quarter 10Q Completed
2019 3rd Quarter 10Q Completed
2019 10K Completed
2020 1st Quarter 10Q
2020 2nd Quarter 10Q (Limited Information Stop Sign down Yield Sign up)
2020 3rd Quarter 10Q (The journey ends)
CURRENT INFORMATION
PINK
To qualify for Current Information, a non-reporting Pink company may subscribe to the OTC Disclosure & News Service and publish current information pursuant to OTC Markets’ Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:
Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
Our treatment is a fraction of the cost for current treatment. We will be able to offer a less expensive product that more people will be able to afford and International aid agencies will purchase it to provide to third world countries.
ENZC financial reporting for getting current timeline:
November 5, 2020 (The journey begins)
Supplemental Information - For the year ended 12-31-2018
Supplemental Information - For the period ended March 31, 2019
Annual Report - Annual Report for the Year Ended December 31, 2018
November 13, 2020 (8 days after last report)
Quarterly Report - For the period ended March 31, 2019
November 20, 2020 (7 days after last report)
Quarterly Report - For the period ended June 30, 2019
Supplemental Information - For the period ended June 30, 2019
Supplemental Information - For the period ended September 30, 2019
November 24, 2020 (4 days after last report)
Quarterly Report - For the period ended September 30, 2019
December 2, 2020 (8 days after last report)
Supplemental Information - Supplemental Information for the Year Ended December 31, 2019
December 8, 2020 (6 days after last report)
Annual Report - Annual Report for the Year Ended December 31, 2019
Based on the previous released reports one can expect more reports to be released:
December 7-11, 2020
2019 10K Released December 8, 2020
2020 1st Quarter 10Q
December 14-18, 2020
2020 2nd Quarter 10Q
2020 3rd Quarter 10Q
Reports needed for Current Information: 3
2018 10K Completed
2019 1st Quarter 10Q Completed
2019 2nd Quarter 10Q Completed
2019 3rd Quarter 10Q Completed
2019 10K Completed
2020 1st Quarter 10Q
2020 2nd Quarter 10Q (Limited Information Stop Sign down Yield Sign up)
2020 3rd Quarter 10Q (The journey ends)
CURRENT INFORMATION
PINK
To qualify for Current Information, a non-reporting Pink company may subscribe to the OTC Disclosure & News Service and publish current information pursuant to OTC Markets’ Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:
Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
Attorney Letter covering all relevant information for non-audited companies
The Company Profile has been verified through OTCIQ
https://www.otcmarkets.com/corporate-services/information-for-pink-companies#:~:text=To%20qualify%20for%20Current%20Information,on%20www.otcmarkets.com.
5 reports completed in the past month with 3 to follow has been accomplished by ENZC. They are getting the job done and we are almost there.
My timeline is just an opinion and it all can be completed any day now.
It is better for the company to announce public events such as they have a Provisional Patent than for the world to find out via social media.
If it is something different such as a private matter like a contract than they can announce when they see fit unless they are current.
Say What...
The new proprietary technology will be developed by ENZC in combination with its ongoing development of monoclonal antibodies against both HIV and the CoronaVirus in our recently established laboratory facility at Texas A & M University 's Institute for Preclinical Studies .
"We believe that with this new technology and our new facilities, the Company will continue to unlock opportunities to expand the use of our existing technologies and develop new therapeutic products as well", explained Harry Zhabilov, CSO of the Company.
Charles Cotropia , CEO stated, "The management team at ENZC is focused on the development of its proprietary technologies and this is a continuation of what is expected to be an expanding pipeline of products for treating serious illnesses."
Fact Sheet: Explaining Operation Warp Speed
What's the goal?
Operation Warp Speed's goal is to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
How will the goal be accomplished?
By investing in and coordinating countermeasure development, OWS will allow countermeasures such as a vaccine to be delivered to patients more rapidly while adhering to standards for safety and efficacy.
Who's working on Operation Warp Speed?
OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD). OWS engages with private firms and other federal agencies, including the Department of Veterans Affairs. It will coordinate existing HHS-wide efforts, including the NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH's Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA.
What's the plan and what's happened so far?
Development
To accelerate development while maintaining standards for safety and efficacy, OWS has been selecting the most promising countermeasure candidates and providing coordinated government support.
Protocols for the demonstration of safety and efficacy are being aligned, which will allow the trials to proceed more quickly, and the protocols for the trials will be overseen by the federal government, as opposed to traditional public-private partnerships, in which pharmaceutical companies decide on their own protocols. Rather than eliminating steps from traditional development timelines, steps will proceed simultaneously, such as starting manufacturing of the vaccine at industrial scale well before the demonstration of vaccine efficacy and safety as happens normally. This increases the financial risk, but not the product risk.
Operation Warp Speed isn’t an agency as such, but rather a mechanism to coordinate among private companies and an array of U.S. government bodies: the Department of Defense, HHS, the Food and Drug Administration, the Centers for Disease Control and Prevention, and beyond. More than 600 people in HHS and 90 people from the DOD are involved. “It’s a coordination activity that helps to cut through the bureaucracy faster,” says Paul Stoffels, chief scientific officer at Johnson & Johnson. OWS has awarded more than $12 billion in vaccine-related contracts and has an overall budget of as much as $18 billion.
Companies Role Amount Invested
Emergent Manufacturing $628m
Texas A&M with Fujifilm Manufacturing $265m
Corning Vials $204m
Si02 Vials $143m
ApiJect Syringes $138m
Grand River Aseptic Fill-finish $160m
Cytiva Manufacturing $31m
Enzolytics ????
Don't know how long ENZC been working on CoronaVirus however it has been for a few months minimum and probably much much longer:
Enzolytics, Inc. Shares BioClonetics Immunotherapeutics, Inc. Company Update
Published: Oct 19, 2020
PLANO, TX / ACCESSWIRE / October 19, 2020 / Enzolytics, Inc. (OTC PINK:ENZC)( "ENZC" or the "Company") today shared the update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), to its Investors, Shareholders and Supporters. The full content of the update is presented below.
Dear Investors and Supporters,
In these trying times caused by the Coronavirus pandemic, we sincerely hope all of you are doing well. We all look to a brighter future. We have been continuously engaged as a part of the effort to address this health crisis and we appreciate all of your support making our ongoing efforts possible.
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
As we have reported earlier, we have applications pending with the National Institute of Health (NIH) and the National Science Foundation (NSF) for further development of our anti-HIV monoclonal antibodies and our proposed production of anti-SARS-CoV-2 (Coronavirus) antibodies. These applications are being reviewed now. Without regard to the success or lack of success of these applications, our combination of technologies with Enzolytics will provide funding for our direct progress with the precise proposals now submitted to the NIH and NSF. As outlined in detail in these applications, we will use our proprietary methodology to produce additional monoclonal antibodies against HIV that specifically target conserved, immutable sites on the virus. Recall that others, including the NIH in conjunction with Vaccine Research Center attempted for years to produce monoclonal antibodies against HIV and failed because of "virus escape" - a euphonism for the fact that their antibodies targeted a site that mutates allowing the virus to "escape" over time.
The critical nature of targeting immutable sites on the Coronavirus will be the same. I note the recent news that Eli Lilly has paused its anti-Coronavirus monoclonal antibody trials. We are not privy to the underlying reasons for such pause, but this could be due to failure to target immutable sites on the virus or on the methodology for producing the monoclonal antibodies. When we recently asked Eli Lilly for the identity of the binding sites for its anti-Coronavirus monoclonal antibodies, they were unable to share that information with us. The fact is that multiple neutralizing antibodies will be necessary to control the Coronavirus, just as is the case with HIV. Our program is to produce multiple antibodies each targeting conserved, immutable sites on the virus.
As to the way we will identify the more effective epitopes (binding sites) on the Coronavirus to target, we recognize that the structure of the Coronavirus is correlative to that of the HIV virus. Because our anti-HIV monoclonal antibodies have been proven to neutralize the HIV virus in 5 international lab testing programs, and because we know the binding site on the HIV virus to which our antibodies bind resulting in neutralization, this knowledge provides insight necessary to identifying the structure (the amino acid sequence) on the Coronavirus we expect is at least one "Achilles Heel" of the Coronavirus. From this knowledge, a monoclonal antibody can be produced against this site that is expectedly virus neutralizing.
Additionally, we will use AI (artificial intelligence) to analyze the 16,000 known sequences of different SARS-Cov-2 viruses that have now been catalogued in the Los Alamos National Laboratory, with multiple different strains identified. By using computer analysis, several conserved (expectedly immutable and neutralizable) sites on the virus can be identified and additional monoclonal antibodies produced against these- to be used in a monoclonal antibody "cocktail". We all have now heard of the "monoclonal antibody cocktail" administered to President Donald Trump. This is exactly what we propose - note that there are numerous different anti-SARS-Cov-2 monoclonal antibodies that can exist - some disease neutralizing and some perhaps of no benefit and some perhaps disease enhancing. Recall that the NIH and big pharma tried for 35 years to produce neutralizing antibodies against HIV and failed - notable evidence being the millions spent of the monoclonal antibodies VRC01 and VRC02 - produced by Vaccine Research Center in conjunction the NIH - both failed in trials because of "virus escape" - meaning they "targeted a site on the virus that mutates and thus the virus escapes the therapeutic effect". The key is to produce monoclonal antibodies that target a conserved, immutable site on the virus such that the virus cannot mutate around the antibody therapeutic.
There are other pharma labs that are attempting to produce anti-Coronavirus monoclonal antibodies. We welcome such efforts as more than one antibody can be expected to needed be provided a successful therapy. And as the virus mutates, additional anti-monoclonal antibodies will be needed.
We do however note the procedure used by other pharma companies for producing these antibodies differs significantly from ours. Other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified Coronavirus proteins.
In contrast, our procedure model starts with human "immune-B cells" that have been obtained from convalescent individuals who have recovered from the Coronavirus. The primary distinction of our process for creating fully human monoclonals is the starting point is from human "immune-B cells" from humans who have survived successfully from a "natural" Coronavirus infection. Our antibodies will retain the original natural antibody affinity and specificity, and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
For full release see:
https://www.biospace.com/article/releases/enzolytics-inc-shares-bioclonetics-immunotherapeutics-inc-company-update/
Effective monoclonal antibodies for CoronaVirus are needed now as the ones on the market are not all that effective.
ENZC can and probably have been working on therapies for both HIV and CoronaVirus at the same time. They are going through the certification phase for the anti HIV treatment.
ENZC is now developing monoclonal antibodies for treating the CoronaVirus.
CEOCFO: Mr. Cotropia, what is the concept behind Enzolytics, Inc?
Mr. Cotropia: Enzolytics, Inc. is a drug development company with two separate but complementary therapy platforms for treating infectious diseases, including treatment for HIV. One technology, invented by Harry Zhabilov, the CSO of our company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, this therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy; specifically, in 68% of those individuals tested, there was an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes decreased. And the viral load in 80.5% of those tested was below the threshold of detection.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
The Company is now combining this technology with recently acquired technology, created by BioClonetics Immunotherapeutics, for creating fully human anti-monoclonal antibodies for treating HIV. Using this technology, the Company has produced a fully human anti-monoclonal antibody that has been tested in 5 international labs where it neutralized over 95% of all strains of the HIV virus against which it was tested. Additional neutralizing antibodies are being produced.
The therapies of Enzolytics’ two technologies, that produced by Enzolytics and that created by BioClonetics, are expected to be synergistic. Additionally, because the HIV virus and the CoronaVirus have correlative structures and with our knowledge of how our monoclonal antibodies neutralize HIV, we are now developing monoclonal antibodies for treating the CoronaVirus.
You can read the entire interview at:
https://www.ceocfointerviews.com/enzolytics20.html
You NAILED it!
Tell that to the company!
ENZC is now developing monoclonal antibodies for treating the CoronaVirus.
CEOCFO: Mr. Cotropia, what is the concept behind Enzolytics, Inc?
Mr. Cotropia: Enzolytics, Inc. is a drug development company with two separate but complementary therapy platforms for treating infectious diseases, including treatment for HIV. One technology, invented by Harry Zhabilov, the CSO of our company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, this therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy; specifically, in 68% of those individuals tested, there was an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes decreased. And the viral load in 80.5% of those tested was below the threshold of detection.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
The Company is now combining this technology with recently acquired technology, created by BioClonetics Immunotherapeutics, for creating fully human anti-monoclonal antibodies for treating HIV. Using this technology, the Company has produced a fully human anti-monoclonal antibody that has been tested in 5 international labs where it neutralized over 95% of all strains of the HIV virus against which it was tested. Additional neutralizing antibodies are being produced.
The therapies of Enzolytics’ two technologies, that produced by Enzolytics and that created by BioClonetics, are expected to be synergistic. Additionally, because the HIV virus and the CoronaVirus have correlative structures and with our knowledge of how our monoclonal antibodies neutralize HIV, we are now developing monoclonal antibodies for treating the CoronaVirus.
You can read the entire interview at:
https://www.ceocfointerviews.com/enzolytics20.html